Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

“With 3 years of follow-up now, the majority of patients achieved a response [with blinatumomab plus ponatinib].”

Hannah Goulart, MD, a hematology oncology fellow at The University of Texas MD Anderson Cancer Center, discussed long-term follow-up findings from a phase 2 trial (NCT03263572) investigating first-line blinatumomab (Blincyto) plus ponatinib (Iclusig) in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Related Content:

ASH Annual Meeting and ExpositionThe University of Texas MD Anderson Cancer CenterOncLive TVHematologic OncologyConference
Pirtobrutinib Delivers Strong Responses and Durable Benefit in Pretreated CLL/SLL in Final BRUIN Analysis
“Smart” Strategy of Up-front Targeted Therapy Reduces Need for Chemo in LBCL
INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis